Genencell Co. Ltd.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Private
- Established
- 2016-08-26
- Employees
- -
- Market Cap
- -
- Website
- http://www.genencell.co.kr
Clinical Trials
11
Active:0
Completed:6
Trial Phases
3 Phases
Phase 2:2
Phase 3:2
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
3 (37.5%)Phase 2
2 (25.0%)Phase 3
2 (25.0%)phase_2_3
1 (12.5%)Efficacy and Safety of ES16001 in Patients With COVID-19
Phase 2
Recruiting
- Conditions
- COVID-19
- Interventions
- Drug: ES16001 40 mgDrug: ES16001 80 mgDrug: ES16001 160 mgDrug: Placebo
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Genencell Co. Ltd.
- Target Recruit Count
- 706
- Registration Number
- NCT05525182
- Locations
- π°π·
Soon Chun Hyang University Hospital, Bucheon, Korea, Republic of
π°π·Eunpyeong, St.Mary's Hospital, Seoul, Korea, Republic of
π°π·Kyung Hee University Medical Center, Seoul, Korea, Republic of
News
No news found